文献速递消化道肿瘤放疗姑息放疗与转移瘤

直肠癌放疗后的肿瘤消退——来自随机斯德哥尔摩III期试验的结果

Tumour regression after radiotherapy for rectal cancer - Results from the randomised Stockholm III trial.
PubMed 文献 · Radiother Oncol · 2019-04-01

斯德哥尔摩III期试验将840例直肠癌患者随机分为短程放疗后1周内手术、短程放疗后4-8周手术及长程放疗后4-8周手术三组,本亚组研究由一名对治疗设盲的病理科医师按Dworak系统评估318例、285例和94例患者的肿瘤消退。短程放疗延迟手术组病理完全缓解率约10%,优于长程放疗组;病理完全缓解及Dworak 4级与更优总生存和无复发生存相关。

要点

  • 短程放疗后延迟4-8周手术组病理完全缓解率10.4%,高于长程放疗组的2.2%。
  • 病理完全缓解者总生存HR 0.51(95%CI 0.26-0.99,P=0.046),无复发生存HR 0.27(95%CI 0.09-0.86,P=0.027)。
  • 短程放疗后延迟手术组肿瘤分期显著更低。

核心结论

  • 短程放疗后延迟4-8周手术可使约10%的患者达到病理完全缓解,在这方面优于25次2 Gy长程放疗。
  • 肿瘤完全缓解、Dworak系统TRG 4级或病理完全缓解与更优的总生存和无复发生存相关。

研究设计与样本

  • 斯德哥尔摩III期随机试验的亚组研究,840例直肠癌患者随机分入短程放疗后1周内手术组、短程放疗后4-8周手术组和长程放疗后4-8周手术组。
  • 本亚组分析纳入短程放疗组318例、短程放疗延迟手术组285例和长程放疗延迟手术组94例。
  • 所有可获得的显微切片由一名对治疗设盲的病理科医师按Dworak系统评估肿瘤消退分级、TNM分期及其他标准组织病理学特征。
  • 患者数据来自瑞典结直肠癌登记处,中位随访5.7年。

主要发现

  • 短程放疗后延迟手术组肿瘤分期显著更低。
  • 病理完全缓解在短程放疗组为1例(0.3%)、短程放疗延迟手术组为29例(10.4%)、长程放疗延迟手术组为2例(2.2%)。
  • 病理完全缓解对比非病理完全缓解的总生存HR为0.51(95%CI 0.26-0.99,P=0.046),无复发生存HR为0.27(95%CI 0.09-0.86,P=0.027)。
  • 病理完全缓解和Dworak 4级均与更优生存相关。

关键数值与推荐

  • 肿瘤消退按Dworak系统分级(TRG)。
  • 病理完全缓解率:短程放疗组0.3%(1例)、短程放疗延迟手术组10.4%(29例)、长程放疗延迟手术组2.2%(2例)。
  • 病理完全缓解对比非病理完全缓解:总生存HR 0.51(95%CI 0.26-0.99,P=0.046),无复发生存HR 0.27(95%CI 0.09-0.86,P=0.027)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Neoadjuvant radiotherapy (RT) in rectal cancer induces tumour regression with a possible complete response (pCR). The optimal fractionation and timing to surgery is not established. The Stockholm III trial randomly assigned 840 patients to 5 × 5 Gy surgery within one week (SRT), 5 × 5 Gy with surgery after 4-8 weeks, and 2 Gy × 25 with surgery after 4-8 weeks (LRT-delay). The aim of this substudy was to assess tumour regression and correlation to survival. MATERIAL AND METHODS: All available microscopy slides were assessed by one pathologist, blinded to treatment, regarding tumour regression, graded according to the Dworak system (TRG), TNM-stage and other standard histopathology characteristics. Patients' data were collected from the Swedish ColoRectal Cancer Registry. Outcomes were TRG, pCR-rates, overall survival (OS) and time to recurrence (TTR). RESULTS: 318, 285 and 94 patients were included in the SRT, SRT-delay and LRT-delay groups. Median follow up was 5.7 years. There were significantly lower tumour stages after SRT-delay. pCR was seen in 1 (0.3%), 29 (10.4%) and 2 (2.2%) patients in SRT, SRT-delay and LRT-delay, respectively. The pCR and Dworak grade 4 were associated with superior survival. pCR vs no-pCR Hazard Ratio (95% Confidence Interval) OS: 0.51 (0.26-0.99) p = 0.046, TTR: 0.27 (0.09-0.86) p = 0.027. CONCLUSION: SRT-delay induces pCR in about 10% of the patients and is in this aspect superior to 25 × 2 Gy. A complete tumour response, TRG 4 using the Dworak system, or a pCR, is associated with superior OS and TTR.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Erlandsson J, Lörinc E, Ahlberg M, et al. Tumour regression after radiotherapy for rectal cancer - Results from the randomised Stockholm III trial. Radiother Oncol. 2019. PMID: 31015165. doi:10.1016/j.radonc.2019.03.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。